Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.

Russell MoserJames AnnisOlga NikolovaCliff WhatcottKay E GurleyEduardo MendezKim Moran-Jones Craig Dorrell Rosalie C SearsCalvin KuoHaiyong Han Andrew V BiankinCarla GrandoriDaniel D Von HoffChristopher J Kemp

Published in: Cancer research (2022)

This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer.

Keyphrases

wild type
oxidative stress
endoplasmic reticulum stress
cell death
genome wide
cell cycle arrest
single cell
cancer therapy
gene expression
dna methylation
cell proliferation